Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B Study 19802

Cancer

Volumn 119, Issue 1, 2013, Pages 90-98

  Stock, Wendy ^a   Johnson, Jeffrey L ^b   Stone, Richard M ^c   Kolitz, Jonathan E ^d   Powell, Bayard L ^e   Wetzler, Meir ^g   Westervelt, Peter ^h   Marcucci, Guido ^f   Deangelo, Daniel J ^c   Vardiman, James W ^a   McDonnell, Diane ^a   Mrõzek, Krzysztof ^f   Bloomfield, Clara D ^f   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h USA   (United States)

Author keywords

adults with acute lymphoblastic leukemia; central nervous system prophylaxis; cytarabine; daunorubicin; dose intensification; phase 2 study

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA; CANCER AND LEUKEMIA GROUP B STUDY 19802; CANCER PATIENT; CARDIOMYOPATHY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM LEUKEMIA; CLINICAL STUDY; CONTROLLED STUDY; CYTOPENIA; DISEASE FREE SURVIVAL; DRUG DOSE INTENSIFICATION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUCOSAL TOXICITTY; OVERALL SURVIVAL; PRIORITY JOURNAL; SKULL IRRADIATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TOXICITY; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 84872825239     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27617     Document Type: Article

References (37)

1. Bassan R, Pogliani E, Casula P, et al. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups. Hematol J. 2001; 2: 117-126.
2. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000; 14: 1307-1325, ix.
3. Hofmann WK, Seipelt G, Langenhan S, et al. Prospective randomized trial to evaluate 2 delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol. 2002; 81: 570-574.
4. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
5. Larson RA,. The US trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004; 83 (suppl 1): S127-S128.
6. Larson RA, Dodge RK, Burns CP, et al. A 5-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995; 85: 2025-2037.
7. Le QH, Thomas X, Ecochard R, et al. Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: Adult Acute Lymphoblastic Leukemia-94 Trial. Cancer. 2007; 109: 2058-2067.
8. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111: 1827-1833.
9. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004; 22: 4075-4086.
10. Bassan R, Pogliani E, Lerede T, et al. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. Haematologica. 1999; 84: 1088-1093.
11. Bassan R, Rohatiner AZ, Lerede T, et al. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. Hematol J. 2000; 1: 226-234.
12. Linker C, Damon L, Ries C, Navarro W,. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20: 2464-2471.
13. Todeschini G, Tecchio C, Meneghini V, et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998; 12: 144-149.
14. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM,. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995; 86: 2091-2097.
15. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002; 16: 1099-1111.
16. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
17. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000; 95: 3310-3322.
18. Abromowitch M, Ochs J, Pui CH, Fairclough D, Murphy SB, Rivera GK,. Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications. Blood. 1988; 71: 866-869.
19. Kamen BA,. L-asparaginase and methotrexate combinations: clashes of empiric success and laboratory models? J Pediatr Hematol Oncol. 2007; 29: 587-588.
20. Winick N, Shuster JJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol. 1996; 14: 2803-2811.
21. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109: 3189-3197.
22. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93: 3983-3993.
23. Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood. 1984; 64: 267-274.
24. Thomas D, O'Brien S, Faderl S, et al. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer. 2010; 116: 4580-4589.
25. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood. 1996; 87: 3135-3142.
26. Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica. 2002; 87: 154-166.
27. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet. 2007; 369: 123-131.
28. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO,. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005; 129: 734-745.
29. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111: 2548-2555.
30. Sancho JM, Ribera JM, Oriol A, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006; 106: 2540-2546.
31. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774-780.
32. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R,. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004; 18: 2032-2035.
33. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112: 1646-1654.
34. DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 587.
35. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27: 911-918.
36. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008; 26: 1843-1849.
37. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28: 3880-3889.